Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization : a propensity-matched study
© 2023. International Cancer Imaging Society (ICIS)..
PURPOSE: To investigate the efficacy and safety of tyrosine-kinase inhibitor (TKI) combined with iodine-125 seed brachytherapy (TKI-I) versus TKI alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
METHODS: Data of patients with TACE-refractory HCC who received TKI (sorafenib or lenvatinib) or TKI-I from September 2018 to December 2020 were retrospectively analyzed. A propensity score matching (PSM) was performed to diminish potential bias. The primary endpoints were overall survival (OS) and time to progression (TTP). Tumor responses and treatment-related adverse events (TRAEs) were also compared between the two groups.
RESULTS: A total of 132 patients were included in this study. Under PSM, 48 paired patients were selected for comparison. The median OS was 23.2 (95% CI 20.9-25.1) months in the TKI-I group versus 13.9 (95% CI 11.1-16.7) months in the TKI group (P < 0.001). The median TTP was 12.8 (95% CI 10.1-15.5) months in the TKI-I group versus 5.8 (95% CI 5.0-6.6) months in the TKI group (P < 0.001). Patients in the TKI-I group had higher objective response rate (68.8% vs. 33.3%, P = 0.001) and disease control rate (89.6% vs. 66.7%, P = 0.007) than those in the TKI group. The incidence and severity of TRAEs in the TKI-I group were comparable to those in the TKI group (any grade, 89.7% vs. 92.2%, P = 0.620; ≥grade 3, 33.8% vs. 32.8%, P = 0.902).
CONCLUSIONS: TKI-I was safe and significantly improved survival over TKI alone in HCC patients with TACE refractoriness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Cancer imaging : the official publication of the International Cancer Imaging Society - 23(2023), 1 vom: 25. Sept., Seite 91 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Yongjian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.09.2023 Date Revised 13.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s40644-023-00604-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362459924 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362459924 | ||
| 003 | DE-627 | ||
| 005 | 20231227131638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40644-023-00604-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM362459924 | ||
| 035 | |a (NLM)37749616 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Yongjian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization |b a propensity-matched study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. International Cancer Imaging Society (ICIS). | ||
| 520 | |a PURPOSE: To investigate the efficacy and safety of tyrosine-kinase inhibitor (TKI) combined with iodine-125 seed brachytherapy (TKI-I) versus TKI alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE) | ||
| 520 | |a METHODS: Data of patients with TACE-refractory HCC who received TKI (sorafenib or lenvatinib) or TKI-I from September 2018 to December 2020 were retrospectively analyzed. A propensity score matching (PSM) was performed to diminish potential bias. The primary endpoints were overall survival (OS) and time to progression (TTP). Tumor responses and treatment-related adverse events (TRAEs) were also compared between the two groups | ||
| 520 | |a RESULTS: A total of 132 patients were included in this study. Under PSM, 48 paired patients were selected for comparison. The median OS was 23.2 (95% CI 20.9-25.1) months in the TKI-I group versus 13.9 (95% CI 11.1-16.7) months in the TKI group (P < 0.001). The median TTP was 12.8 (95% CI 10.1-15.5) months in the TKI-I group versus 5.8 (95% CI 5.0-6.6) months in the TKI group (P < 0.001). Patients in the TKI-I group had higher objective response rate (68.8% vs. 33.3%, P = 0.001) and disease control rate (89.6% vs. 66.7%, P = 0.007) than those in the TKI group. The incidence and severity of TRAEs in the TKI-I group were comparable to those in the TKI group (any grade, 89.7% vs. 92.2%, P = 0.620; ≥grade 3, 33.8% vs. 32.8%, P = 0.902) | ||
| 520 | |a CONCLUSIONS: TKI-I was safe and significantly improved survival over TKI alone in HCC patients with TACE refractoriness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brachytherapy | |
| 650 | 4 | |a Combined modality therapy | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Therapeutic chemoembolization | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 650 | 7 | |a Iodine-125 |2 NLM | |
| 650 | 7 | |a GVO776611R |2 NLM | |
| 650 | 7 | |a Tyrosine |2 NLM | |
| 650 | 7 | |a 42HK56048U |2 NLM | |
| 650 | 7 | |a Tyrosine Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Wu, Jingqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Licong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Kangshun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jingwen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Liteng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Bihui |e verfasserin |4 aut | |
| 700 | 1 | |a He, Mingji |e verfasserin |4 aut | |
| 700 | 1 | |a Lian, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wensou |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Mingyue |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer imaging : the official publication of the International Cancer Imaging Society |d 2000 |g 23(2023), 1 vom: 25. Sept., Seite 91 |w (DE-627)NLM15769819X |x 1470-7330 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:25 |g month:09 |g pages:91 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40644-023-00604-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 25 |c 09 |h 91 | ||